Drug Trial Radar · NCT00377676
Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Jun 10, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,095
Actual
Start
Jul 2004
Primary completion
Jan 2007
Study completion Jan 2007
Sponsor
- Lead sponsor
- VeroScienceIndustry
- Sponsor type
- Industry
- First posted
- Sep 18, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cycloset, a new quick-release oral formulation of bromocriptine mesylate, effectively reduces blood sugar by the proposed mechanism of reversing many of the metabolic alterations associated with insulin resistance and obesity by resetting central (hypothalamic) circadian organization of monoamine neuronal activities. The primary analysis of this study will test the hypothesis that the rate of all-cause severe adverse events for those receiving usual drug therapy for diabetes management plus Cycloset is not greater than that for usual drug therapy plus placebo by more than an acceptable margin. While the primary purpose of this study is to establish the safety profile of Cycloset in type 2 diabetes, any potential positive cardiovascular benefits will be evaluated as well.
Conditions
- Type 2 Diabetes Mellitus
Interventions
CyclosetDrug
Usual diabetes therapy plus Cycloset
Usual Diabetes Therapy plus placeboDrug
Placebo tablet taken orally once in the morning, beginning with one tablet daily, titrated up by 1 tablet each week to a maximum of 6 tablets daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Subjects Experiencing Serious Adverse EventsTime frame: From baseline to week 52.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.